NPC 15437 Interacts with the C1 Domain of Protein Kinase C. An Analysis Using Mutant PKC Constructs
Overview
Affiliations
We recently demonstrated that 2,6,diamino-N-[( 1-(oxotridecyl)-2-piperidinyl]methyl)-hexanamide (NPC 15437) is a selective inhibitor of PKC interacting at the regulatory domain of the enzyme. To further investigate the interaction of NPC 15437 with PKC we expressed a series of cDNAs encoding mutant PKC molecules in COS7 cells. NPC 15437 had no effect on the protein kinase activity of mutants lacking the N-terminal region of the C1 domain. Further, NPC 15437 was a competitive inhibitor of the activation of PKC alpha by phorbol ester and attenuated the binding of phorbol ester to the enzyme in intact cells. The present study demonstrates that mutant enzyme constructs can be used to localize the site of interaction of NPC 15437 with PKC to residues 12-42, which encodes the pseudosubstrate binding domain and part of the first cysteine-rich repeat sequence.
Yamahashi Y, Lin Y, Mouri A, Iwanaga S, Kawashima K, Tokumoto Y Mol Psychiatry. 2022; 27(8):3479-3492.
PMID: 35665767 PMC: 9708603. DOI: 10.1038/s41380-022-01643-2.
Activators and Inhibitors of Protein Kinase C (PKC): Their Applications in Clinical Trials.
Kawano T, Inokuchi J, Eto M, Murata M, Kang J Pharmaceutics. 2021; 13(11).
PMID: 34834162 PMC: 8621927. DOI: 10.3390/pharmaceutics13111748.
Spinal activation of protein kinase C elicits phrenic motor facilitation.
Devinney M, Mitchell G Respir Physiol Neurobiol. 2017; 256:36-42.
PMID: 29081358 PMC: 6225774. DOI: 10.1016/j.resp.2017.10.007.
Phrenic long-term facilitation requires PKCθ activity within phrenic motor neurons.
Devinney M, Fields D, Huxtable A, Peterson T, Dale E, Mitchell G J Neurosci. 2015; 35(21):8107-17.
PMID: 26019328 PMC: 4444536. DOI: 10.1523/JNEUROSCI.5086-14.2015.
Strey K, Nichols N, Baertsch N, Broytman O, Baker-Herman T J Neurosci. 2012; 32(46):16510-20.
PMID: 23152633 PMC: 3530258. DOI: 10.1523/JNEUROSCI.2631-12.2012.